News

The study demonstrated that the higher, antimicrobial dose does not provide a greater clinical benefit than the anti-inflammatory dose of 40mg, controlled release. However, the higher dose was

The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment will be included in Vical’s year-end 2007 cash balances, consistent

One of the major aims of the research is to create ways of increasing the level of HDL cholesterol in the bloodstream using VIRxSYS’s patented spliceosome-mediated RNA trans-splicing

In addition, Theravance has granted the underwriters a 30-day option to purchase on the same terms and conditions up to an additional $22.5 million aggregate principal amount of

APP’s Granisetron is AP-rated, preservative and latex-free, and bar-coded. Granisetron hydrochloride injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of

Invitrogen will commercialize these sequences over the next few years, allowing the company to expand its NCode microRNA microarray product line into the field of non-coding RNA profiling.

Targacept has granted to the underwriters for the offering, a 30-day option to purchase up to 570,000 additional shares of common stock to cover over-allotments, if any. All

The RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial is a global, multi-center, non-inferiority, randomized trial comparing two blinded doses (150mg twice daily or 110mg twice daily)

The acquisition, partially funded with seller financing will be immediately accretive and is expected to add $10 million in annual revenues to Graymark Healthcare. Stanton Nelson, CEO of